{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T01:59:18Z","timestamp":1778637558015,"version":"3.51.4"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012681","name":"Universit\u00e4tsklinikum K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012681","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>With the advent of new targeted drugs in hematology and oncology patient prognosis is improved. Combination with antifungal prophylaxis challenges clinicians due to pharmacological profiles prone to drug\u2013drug interactions (DDI). Midostaurin is a novel agent for <jats:italic>FLT3<\/jats:italic>-TKD\/-ITD<jats:sup>mut<\/jats:sup>-acute myeloid leukemia (AML) and metabolized via cytochrome P450 3A4 (CYP3A4). Posaconazole is a standard of care antifungal agent used for prophylaxis during induction treatment of AML and a strong CYP3A4 inhibitor. Concomitant administration of both drugs leads to elevated midostaurin exposure. Both drugs improve overall survival at low numbers needed to treat. The impact of CYP3A4-related DDI remains to be determined. Severe adverse events have been observed; however, it remains unclear if they can be directly linked to DDI. The lack of prospective clinical studies assessing incidence of invasive fungal infections and clinical impact of DDI contributes to neglecting live-saving antifungal prophylaxis. Management strategies to combine both drugs have been proposed, but evidence on which approach to use is scarce. In this review, we discuss several approaches in the specific clinical setting of concomitant administration of midostaurin and posaconazole and give examples from everyday clinical practice. Therapeutic drug monitoring will become increasingly important to individualize and personalize antineoplastic concomitant and antifungal treatment in the context of DDI. Pharmaceutical companies addressing the issue in clinical trials may take a pioneer role in this field. Other recently developed and approved drugs for the treatment of AML likely inhere potential of DDI marking a foreseeable issue in future treatment of this life-threatening disease.<\/jats:p>","DOI":"10.1007\/s00277-020-04107-1","type":"journal-article","created":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T21:02:32Z","timestamp":1591650152000},"page":"1429-1440","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma"],"prefix":"10.1007","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9152-2469","authenticated-orcid":false,"given":"Jannik","family":"Stemler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7386-7495","authenticated-orcid":false,"given":"Philipp","family":"Koehler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4388-5163","authenticated-orcid":false,"given":"Christian","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2861-9185","authenticated-orcid":false,"given":"Carsten","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9599-3137","authenticated-orcid":false,"given":"Oliver A.","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,8]]},"reference":[{"issue":"10","key":"4107_CR1","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1002\/ajh.25214","volume":"93","author":"EH Estey","year":"2018","unstructured":"Estey EH (2018) Acute myeloid leukemia: 2019 update on risk-stratification and management. Am J Hematol 93(10):1267\u20131291. https:\/\/doi.org\/10.1002\/ajh.25214","journal-title":"Am J Hematol"},{"key":"4107_CR2","unstructured":"SEER Cancer Stat Facts: Leukemia\u2014acute myeloid leukemia. (2020) National Cancer Institute. https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html. Accessed 04-01-2020"},{"issue":"5","key":"4107_CR3","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","volume":"100","author":"DG Gilliland","year":"2002","unstructured":"Gilliland DG, Griffin JD (2002) The roles of FLT3 in hematopoiesis and leukemia. Blood 100(5):1532\u20131542. https:\/\/doi.org\/10.1182\/blood-2002-02-0492","journal-title":"Blood"},{"issue":"8","key":"4107_CR4","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1182\/blood.v97.8.2434","volume":"97","author":"Y Yamamoto","year":"2001","unstructured":"Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Saito H, Ueda R, Ohno R, Naoe T (2001) Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97(8):2434\u20132439. https:\/\/doi.org\/10.1182\/blood.v97.8.2434","journal-title":"Blood"},{"key":"4107_CR5","doi-asserted-by":"publisher","unstructured":"Levis M (2013) FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? Hematology Am Soc Hematol Educ Program 2013:220\u2013226. https:\/\/doi.org\/10.1182\/asheducation-2013.1.220","DOI":"10.1182\/asheducation-2013.1.220"},{"issue":"13","key":"4107_CR6","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1182\/blood-2002-05-1440","volume":"100","author":"S Frohling","year":"2002","unstructured":"Frohling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K, Dohner H, Dohner K (2002) Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 100(13):4372\u20134380. https:\/\/doi.org\/10.1182\/blood-2002-05-1440","journal-title":"Blood"},{"key":"4107_CR7","doi-asserted-by":"publisher","unstructured":"Pagano L, Akova M, Dimopoulos G, Herbrecht R, Drgona L, Blijlevens N (2011) Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. J Antimicrob Chemother 66(Suppl 1):i5\u2013i14. https:\/\/doi.org\/10.1093\/jac\/dkq437","DOI":"10.1093\/jac\/dkq437"},{"issue":"9","key":"4107_CR8","first-page":"1076","volume":"94","author":"GP Bodey","year":"1966","unstructured":"Bodey GP (1966) Infectious complications of acute leukemia. Med Times 94(9):1076\u20131085","journal-title":"Med Times"},{"issue":"4","key":"4107_CR9","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1056\/NEJMoa061094","volume":"356","author":"OA Cornely","year":"2007","unstructured":"Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh Y-T, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356(4):348\u2013359. https:\/\/doi.org\/10.1056\/NEJMoa061094","journal-title":"N Engl J Med"},{"issue":"4","key":"4107_CR10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa061098","volume":"356","author":"AJ Ullmann","year":"2007","unstructured":"Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356(4):335\u2013347. https:\/\/doi.org\/10.1056\/NEJMoa061098","journal-title":"N Engl J Med"},{"issue":"12","key":"4107_CR11","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1093\/jac\/dkx263","volume":"72","author":"OA Cornely","year":"2017","unstructured":"Cornely OA, Robertson MN, Haider S, Grigg A, Geddes M, Aoun M, Heinz WJ, Raad I, Schanz U, Meyer RG, Hammond SP, Mullane KM, Ostermann H, Ullmann AJ, Zimmerli S, Van Iersel M, Hepler DA, Waskin H, Kartsonis NA, Maertens J (2017) Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. J Antimicrob Chemother 72(12):3406\u20133413. https:\/\/doi.org\/10.1093\/jac\/dkx263","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"4107_CR12","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/jac\/dkv380","volume":"71","author":"OA Cornely","year":"2016","unstructured":"Cornely OA, Duarte RF, Haider S, Chandrasekar P, Helfgott D, Jimenez JL, Candoni A, Raad I, Laverdiere M, Langston A, Kartsonis N, Van Iersel M, Connelly N, Waskin H (2016) Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. J Antimicrob Chemother 71(3):718\u2013726. https:\/\/doi.org\/10.1093\/jac\/dkv380","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"4107_CR13","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2217\/17460913.2.3.231","volume":"2","author":"F Farowski","year":"2007","unstructured":"Farowski F, Vehreschild JJ, Cornely OA (2007) Posaconazole: a next-generation triazole antifungal. Future Microbiol 2(3):231\u2013243. https:\/\/doi.org\/10.2217\/17460913.2.3.231","journal-title":"Future Microbiol"},{"issue":"5","key":"4107_CR14","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.ejps.2004.01.005","volume":"21","author":"D Wexler","year":"2004","unstructured":"Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M (2004) Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 21(5):645\u2013653. https:\/\/doi.org\/10.1016\/j.ejps.2004.01.005","journal-title":"Eur J Pharm Sci"},{"issue":"5","key":"4107_CR15","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Dohner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, Dohner H (2017) Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 377(5):454\u2013464. https:\/\/doi.org\/10.1056\/NEJMoa1614359","journal-title":"N Engl J Med"},{"key":"4107_CR16","unstructured":"RYDAPT\u00ae (midostaurin)\u2014package insert and label information (December 2019). Novartis Pharmaceuticals Corporation, East Hanover"},{"issue":"2","key":"4107_CR17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver N, Schlenk RF, Russell NH, Levis MJ (2019) Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia 33(2):299\u2013312. https:\/\/doi.org\/10.1038\/s41375-018-0357-9","journal-title":"Leukemia"},{"issue":"4","key":"4107_CR18","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1182\/bloodadvances.2017011080","volume":"2","author":"RM Stone","year":"2018","unstructured":"Stone RM, Manley PW, Larson RA, Capdeville R (2018) Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. Blood Adv 2(4):444\u2013453. https:\/\/doi.org\/10.1182\/bloodadvances.2017011080","journal-title":"Blood Adv"},{"issue":"6","key":"4107_CR19","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1182\/bloodadvances.2018022921","volume":"3","author":"YT Chang","year":"2019","unstructured":"Chang YT, Hernandez D, Alonso S, Gao M, Su M, Ghiaur G, Levis MJ, Jones RJ (2019) Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3\/ITD AML from tyrosine kinase inhibitors. Blood Adv 3(6):908\u2013916. https:\/\/doi.org\/10.1182\/bloodadvances.2018022921","journal-title":"Blood Adv"},{"issue":"5","key":"4107_CR20","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/jco.2001.19.5.1485","volume":"19","author":"DJ Propper","year":"2001","unstructured":"Propper DJ, McDonald AC, Man A, Thavasu P, Balkwill F, Braybrooke JP, Caponigro F, Graf P, Dutreix C, Blackie R, Kaye SB, Ganesan TS, Talbot DC, Harris AL, Twelves C (2001) Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 19(5):1485\u20131492. https:\/\/doi.org\/10.1200\/jco.2001.19.5.1485","journal-title":"J Clin Oncol"},{"key":"4107_CR21","doi-asserted-by":"publisher","first-page":"8817","DOI":"10.2147\/CMAR.S177894","volume":"11","author":"HA Abbas","year":"2019","unstructured":"Abbas HA, Alfayez M, Kadia T, Ravandi-Kashani F, Daver N (2019) Midostaurin in acute myeloid leukemia: an evidence-based review and patient selection. Cancer Manag Res 11:8817\u20138828. https:\/\/doi.org\/10.2147\/CMAR.S177894","journal-title":"Cancer Manag Res"},{"issue":"1","key":"4107_CR22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1182\/blood-2004-03-0891","volume":"105","author":"RM Stone","year":"2005","unstructured":"Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD, Grandin W, Lebwohl D, Wang Y, Cohen P, Fox EA, Neuberg D, Clark J, Gilliland DG, Griffin JD (2005) Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 105(1):54\u201360. https:\/\/doi.org\/10.1182\/blood-2004-03-0891","journal-title":"Blood"},{"key":"4107_CR23","unstructured":"Stone RM (2007) A phase III randomized, double-blind study of induction (Daunorubicin\/Cytarabin) and consolidation (high-dose Cytarabine) chemotherapy + Midostaurin (PKC412) (IND # TBD) or placebo in newly diagnosed patients <\u200960 years of age with FLT3 mutated acute myeloid leukemia (AML). Study Protocol"},{"issue":"Suppl 1","key":"4107_CR24","first-page":"3814","volume":"130","author":"T Ouatas","year":"2017","unstructured":"Ouatas T, Duval V, Sinclair K, Berkowitz N (2017) Concomitant use of Midostaurin with strong CYP3A4 inhibitors: an analysis from the Ratify trial. Blood 130(Suppl 1):3814\u20133814","journal-title":"Blood"},{"issue":"6","key":"4107_CR25","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s00280-013-2287-6","volume":"72","author":"C Dutreix","year":"2013","unstructured":"Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y (2013) Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers. Cancer Chemother Pharmacol 72(6):1223\u20131234. https:\/\/doi.org\/10.1007\/s00280-013-2287-6","journal-title":"Cancer Chemother Pharmacol"},{"issue":"28","key":"4107_CR26","doi-asserted-by":"publisher","first-page":"4339","DOI":"10.1200\/jco.2010.28.9678","volume":"28","author":"T Fischer","year":"2010","unstructured":"Fischer T, Stone RM, Deangelo DJ, Galinsky I, Estey E, Lanza C, Fox E, Ehninger G, Feldman EJ, Schiller GJ, Klimek VM, Nimer SD, Gilliland DG, Dutreix C, Huntsman-Labed A, Virkus J, Giles FJ (2010) Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 28(28):4339\u20134345. https:\/\/doi.org\/10.1200\/jco.2010.28.9678","journal-title":"J Clin Oncol"},{"key":"4107_CR27","unstructured":"Food and Drug Aadministration (2017) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/207997s000lbl.pdf. Accessed 05-15-2020"},{"key":"4107_CR28","unstructured":"European Commission (2017) https:\/\/ec.europa.eu\/health\/documents\/community-register\/2017\/20170918138684\/anx_138684_de.pdf. Accessed 05-15-2020"},{"issue":"2","key":"4107_CR29","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00277-017-3196-2","volume":"97","author":"SC Mellinghoff","year":"2018","unstructured":"Mellinghoff SC, Panse J, Alakel N, Behre G, Buchheidt D, Christopeit M, Hasenkamp J, Kiehl M, Koldehoff M, Krause SW, Lehners N, von Lilienfeld-Toal M, Lohnert AY, Maschmeyer G, Teschner D, Ullmann AJ, Penack O, Ruhnke M, Mayer K, Ostermann H, Wolf HH, Cornely OA (2018) Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Ann Hematol 97(2):197\u2013207. https:\/\/doi.org\/10.1007\/s00277-017-3196-2","journal-title":"Ann Hematol"},{"issue":"4","key":"4107_CR30","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","volume":"63","author":"TF Patterson","year":"2016","unstructured":"Patterson TF, Thompson GR III, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young J-AH, Bennett JE (2016) Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 63(4):e1\u2013e60. https:\/\/doi.org\/10.1093\/cid\/ciw326","journal-title":"Clin Infect Dis"},{"issue":"12","key":"4107_CR31","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1093\/jac\/dky286","volume":"73","author":"JA Maertens","year":"2018","unstructured":"Maertens JA, Girmenia C, Bruggemann RJ, Duarte RF, Kibbler CC, Ljungman P, Racil Z, Ribaud P, Slavin MA, Cornely OA, Peter Donnelly J, Cordonnier C (2018) European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother 73(12):3221\u20133230. https:\/\/doi.org\/10.1093\/jac\/dky286","journal-title":"J Antimicrob Chemother"},{"issue":"30","key":"4107_CR32","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1200\/jco.18.00374","volume":"36","author":"RA Taplitz","year":"2018","unstructured":"Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, Langston AA, Nastoupil LJ, Rajotte M, Rolston KV, Strasfeld L, Flowers CR (2018) Antimicrobial prophylaxis for adult patients with Cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol 36(30):3043\u20133054. https:\/\/doi.org\/10.1200\/jco.18.00374","journal-title":"J Clin Oncol"},{"key":"4107_CR33","unstructured":"Noxafil\u00ae (posaconazole)\u2014prescribing information (2019). Merck & Co Inc., Whitehouse Station,"},{"issue":"4","key":"4107_CR34","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s15010-008-7357-z","volume":"36","author":"OA Cornely","year":"2008","unstructured":"Cornely OA (2008) Aspergillus to Zygomycetes: causes, risk factors, prevention, and treatment of invasive fungal infections. Infection 36(4):296\u2013313. https:\/\/doi.org\/10.1007\/s15010-008-7357-z","journal-title":"Infection"},{"issue":"Suppl 5","key":"4107_CR35","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1469-0691.2009.02985.x","volume":"15","author":"OA Cornely","year":"2009","unstructured":"Cornely OA, Vehreschild JJ, Ruping MJ (2009) Current experience in treating invasive zygomycosis with posaconazole. Clin Microbiol Infect 15(Suppl 5):77\u201381. https:\/\/doi.org\/10.1111\/j.1469-0691.2009.02985.x","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"4107_CR36","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.dmpk.2016.05.001","volume":"31","author":"A Petitcollin","year":"2016","unstructured":"Petitcollin A, Crochette R, Tron C, Verdier MC, Boglione-Kerrien C, Vigneau C, Bellissant E, Lemaitre F (2016) Increased inhibition of cytochrome P450 3A4 with the tablet formulation of posaconazole. Drug Metab Pharmacokinet 31(5):389\u2013393. https:\/\/doi.org\/10.1016\/j.dmpk.2016.05.001","journal-title":"Drug Metab Pharmacokinet"},{"issue":"6","key":"4107_CR37","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00228-012-1212-y","volume":"68","author":"JJ Vehreschild","year":"2012","unstructured":"Vehreschild JJ, Muller C, Farowski F, Vehreschild MJ, Cornely OA, Fuhr U, Kreuzer KA, Hallek M, Kohl V (2012) Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. Eur J Clin Pharmacol 68(6):987\u2013995. https:\/\/doi.org\/10.1007\/s00228-012-1212-y","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"4107_CR38","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1128\/aac.05937-11","volume":"56","author":"OA Cornely","year":"2012","unstructured":"Cornely OA, Helfgott D, Langston A, Heinz W, Vehreschild JJ, Vehreschild MJ, Krishna G, Ma L, Huyck S, McCarthy MC (2012) Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection. Antimicrob Agents Chemother 56(5):2652\u20132658. https:\/\/doi.org\/10.1128\/aac.05937-11","journal-title":"Antimicrob Agents Chemother"},{"key":"4107_CR39","unstructured":"CRESEMBA\u00ae (Isavuconazoium)\u2014prescribing information (2019). Astellas Pharma US Inc., Northbrook."},{"key":"4107_CR40","unstructured":"Vfend\u00ae (voriconazole)\u2014precribing information (2019). Pfizer Inc., New York"},{"key":"4107_CR41","unstructured":"Mycamine\u00ae (micafungin)\u2014precribing information (2019). Astellas Pharma Inc., Northbrook."},{"key":"4107_CR42","unstructured":"CANCIDAS\u00ae (caspofungin acetate)\u2014prescribing information (2019). Merck & Co Inc., Whitehouse Station."},{"key":"4107_CR43","doi-asserted-by":"crossref","unstructured":"Petri H (2018) Arzneimitteltherapiesicherheit: Metabolische Interaktionen der Proteinkinase-Inhibitoren. Dtsch Arztebl International 115 (7):[32]","DOI":"10.3238\/PersKardio.2018.03.30.04"},{"issue":"6","key":"4107_CR44","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1097\/qco.0000000000000611","volume":"32","author":"J Lindsay","year":"2019","unstructured":"Lindsay J, Teh BW, Micklethwaite K, Slavin M (2019) Azole antifungals and new targeted therapies for hematological malignancy. Curr Opin Infect Dis 32(6):538\u2013545. https:\/\/doi.org\/10.1097\/qco.0000000000000611","journal-title":"Curr Opin Infect Dis"},{"issue":"5","key":"4107_CR45","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/bjc.2013.48","volume":"108","author":"RWF van Leeuwen","year":"2013","unstructured":"van Leeuwen RWF, Brundel DHS, Neef C, van Gelder T, Mathijssen RHJ, Burger DM, Jansman FGA (2013) Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer 108(5):1071\u20131078. https:\/\/doi.org\/10.1038\/bjc.2013.48","journal-title":"Br J Cancer"},{"key":"4107_CR46","doi-asserted-by":"publisher","unstructured":"Groll AH, Townsend R, Desai A, Azie N, Jones M, Engelhardt M, Schmitt-Hoffman AH, Bruggemann RJM (2017) Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4. Transpl Infect Dis 19(5). https:\/\/doi.org\/10.1111\/tid.12751","DOI":"10.1111\/tid.12751"},{"issue":"1","key":"4107_CR47","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/17425255.2019.1552256","volume":"15","author":"A Pejcic","year":"2019","unstructured":"Pejcic A, Jankovic SM, Opancina V, Babic G, Milosavljevic M (2019) Drug-drug interactions in patients receiving hematopoietic stem cell transplantation. Expert Opin Drug Metab Toxicol 15(1):49\u201359. https:\/\/doi.org\/10.1080\/17425255.2019.1552256","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"10","key":"4107_CR48","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1086\/587177","volume":"46","author":"OA Cornely","year":"2008","unstructured":"Cornely OA, Ullmann AJ (2008) Numbers needed to treat with posaconazole prophylaxis to prevent invasive fungal infection and death. Clin Infect Dis 46(10):1626\u20131627; author reply 1627-1628. https:\/\/doi.org\/10.1086\/587177","journal-title":"Clin Infect Dis"},{"key":"4107_CR49","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.critrevonc.2019.06.011","volume":"141","author":"TM Weis","year":"2019","unstructured":"Weis TM, Marini BL, Bixby DL, Perissinotti AJ (2019) Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia. Crit Rev Oncol Hematol 141:125\u2013138. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.06.011","journal-title":"Crit Rev Oncol Hematol"},{"key":"4107_CR50","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.coph.2015.07.002","volume":"24","author":"VJ Lempers","year":"2015","unstructured":"Lempers VJ, Martial LC, Schreuder MF, Blijlevens NM, Burger DM, Aarnoutse RE, Bruggemann RJ (2015) Drug-interactions of azole antifungals with selected immunosuppressants in transplant patients: strategies for optimal management in clinical practice. Curr Opin Pharmacol 24:38\u201344. https:\/\/doi.org\/10.1016\/j.coph.2015.07.002","journal-title":"Curr Opin Pharmacol"},{"issue":"2","key":"4107_CR51","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s12281-015-0224-3","volume":"9","author":"RJM Br\u00fcggemann","year":"2015","unstructured":"Br\u00fcggemann RJM, Aarnoutse RE (2015) Fundament and prerequisites for the application of an antifungal TDM service. Current Fungal Infection Reports 9(2):122\u2013129. https:\/\/doi.org\/10.1007\/s12281-015-0224-3","journal-title":"Current Fungal Infection Reports"},{"issue":"7\u20138","key":"4107_CR52","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.clinbiochem.2017.01.007","volume":"50","author":"M Oellerich","year":"2017","unstructured":"Oellerich M, Kanzow P, Walson PD (2017) Therapeutic drug monitoring\u2014key to personalized pharmacotherapy. Clin Biochem 50(7\u20138):375\u2013379. https:\/\/doi.org\/10.1016\/j.clinbiochem.2017.01.007","journal-title":"Clin Biochem"},{"issue":"2","key":"4107_CR53","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/s1470-2045(18)30010-x","volume":"19","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, Arellano M, Frattini MG, Kantarjian H, Popovic R, Chyla B, Xu T, Dunbar M, Agarwal SK, Humerickhouse R, Mabry M, Potluri J, Konopleva M, Pollyea DA (2018) Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol 19(2):216\u2013228. https:\/\/doi.org\/10.1016\/s1470-2045(18)30010-x","journal-title":"Lancet Oncol"},{"issue":"23","key":"4107_CR54","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1182\/bloodadvances.2019000930","volume":"3","author":"I Aldoss","year":"2019","unstructured":"Aldoss I, Dadwal S, Zhang J, Tegtmeier B, Mei M, Arslan S, Al Malki MM, Salhotra A, Ali H, Aribi A, Sandhu K, Khaled S, Snyder D, Nakamura R, Stein AS, Forman SJ, Marcucci G, Pullarkat V (2019) Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents. Blood Adv 3(23):4043\u20134049. https:\/\/doi.org\/10.1182\/bloodadvances.2019000930","journal-title":"Blood Adv"},{"key":"4107_CR55","unstructured":"VENCLEXTA\u00ae (venetoclax)\u2014prescribing information (2019). AbbVie Inc., North Chicago"},{"issue":"2","key":"4107_CR56","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","volume":"39","author":"SK Agarwal","year":"2017","unstructured":"Agarwal SK, DiNardo CD, Potluri J, Dunbar M, Kantarjian HM, Humerickhouse RA, Wong SL, Menon RM, Konopleva MY, Salem AH (2017) Management of Venetoclax-Posaconazole Interaction in acute myeloid leukemia patients: evaluation of dose adjustments. Clin Ther 39(2):359\u2013367. https:\/\/doi.org\/10.1016\/j.clinthera.2017.01.003","journal-title":"Clin Ther"},{"issue":"3","key":"4107_CR57","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/ajh.25369","volume":"94","author":"M Mei","year":"2019","unstructured":"Mei M, Aldoss I, Marcucci G, Pullarkat V (2019) Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: update on clinical trial data and practical considerations for use. Am J Hematol 94(3):358\u2013362. https:\/\/doi.org\/10.1002\/ajh.25369","journal-title":"Am J Hematol"},{"key":"4107_CR58","unstructured":"Schlafer D (2019) Management of Midostaurin-CYP3A4 drug-drug interactions in patients with acute myeloid leukemia. Oncology (Williston Park) 33(7)"},{"issue":"8","key":"4107_CR59","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1182\/blood-2018-08-869453","volume":"133","author":"RF Schlenk","year":"2019","unstructured":"Schlenk RF, Weber D, Fiedler W, Salih HR, Wulf G, Salwender H, Schroeder T, Kindler T, Lubbert M, Wolf D, Westermann J, Kraemer D, Gotze KS, Horst HA, Krauter J, Girschikofsky M, Ringhoffer M, Sudhoff T, Held G, Derigs HG, Schroers R, Greil R, Griesshammer M, Lange E, Burchardt A, Martens U, Hertenstein B, Marretta L, Heuser M, Thol F, Gaidzik VI, Herr W, Krzykalla J, Benner A, Dohner K, Ganser A, Paschka P, Dohner H (2019) Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood 133(8):840\u2013851. https:\/\/doi.org\/10.1182\/blood-2018-08-869453","journal-title":"Blood"},{"issue":"5","key":"4107_CR60","doi-asserted-by":"publisher","first-page":"E72","DOI":"10.1002\/ajh.24686","volume":"92","author":"F De Marchi","year":"2017","unstructured":"De Marchi F, Candoni A, Zannier ME, Haley L, Lau BW, Fanin R (2017) Concomitant monitoring of WT1 and FLT3-ITD expression in FLT3-ITD acute myeloid leukemia patients: which should we trust as a minimal residual disease marker? Am J Hematol 92(5):E72\u2013e74. https:\/\/doi.org\/10.1002\/ajh.24686","journal-title":"Am J Hematol"},{"issue":"4","key":"4107_CR61","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/ajh.24667","volume":"92","author":"M Levis","year":"2017","unstructured":"Levis M (2017) FLT3 as a marker of minimal residual disease: time to re-think? Am J Hematol 92(4):329\u2013330. https:\/\/doi.org\/10.1002\/ajh.24667","journal-title":"Am J Hematol"},{"key":"4107_CR62","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/ejh.13372","volume":"104","author":"A Rothe","year":"2019","unstructured":"Rothe A, Classen A, Carney J, Hallek M, Mellinghoff SC, Scheid C, Holtick U, von Bergwelt-Baildon M (2019) Bridging antifungal prophylaxis with 50\u00a0mg or 100\u00a0mg micafungin in allogeneic stem cell transplantation: a retrospective analysis. Eur J Haematol 104:291\u2013298. https:\/\/doi.org\/10.1111\/ejh.13372","journal-title":"Eur J Haematol"},{"issue":"10","key":"4107_CR63","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1086\/422312","volume":"39","author":"JA van Burik","year":"2004","unstructured":"van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, Bunin N, Wall DA, Hiemenz JW, Satoi Y, Lee JM, Walsh TJ (2004) Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39(10):1407\u20131416. https:\/\/doi.org\/10.1086\/422312","journal-title":"Clin Infect Dis"},{"issue":"1","key":"4107_CR64","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1186\/s12885-019-5557-9","volume":"19","author":"H Park","year":"2019","unstructured":"Park H, Youk J, Shin DY, Hong J, Kim I, Kim NJ, Lee JO, Bang SM, Yoon SS, Park WB, Koh Y (2019) Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy. BMC Cancer 19(1):358. https:\/\/doi.org\/10.1186\/s12885-019-5557-9","journal-title":"BMC Cancer"},{"issue":"5","key":"4107_CR65","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.jinf.2016.06.011","volume":"73","author":"S Park","year":"2016","unstructured":"Park S, Kim K, Jang JH, Kim SJ, Kim WS, Chung DR, Kang CI, Peck KR, Jung CW (2016) Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients. J Inf Secur 73(5):496\u2013505. https:\/\/doi.org\/10.1016\/j.jinf.2016.06.011","journal-title":"J Inf Secur"},{"issue":"3","key":"4107_CR66","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jinf.2018.03.015","volume":"77","author":"DJ Epstein","year":"2018","unstructured":"Epstein DJ, Seo SK, Huang YT, Park JH, Klimek VM, Berman E, Tallman MS, Frattini MG, Papanicolaou GA (2018) Micafungin versus posaconazole prophylaxis in acute leukemia or myelodysplastic syndrome: a randomized study. J Inf Secur 77(3):227\u2013234. https:\/\/doi.org\/10.1016\/j.jinf.2018.03.015","journal-title":"J Inf Secur"},{"issue":"17","key":"4107_CR67","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1001\/jama.2019.15702","volume":"322","author":"BT Fisher","year":"2019","unstructured":"Fisher BT, Zaoutis T, Dvorak CC, Nieder M, Zerr D, Wingard JR, Callahan C, Villaluna D, Chen L, Dang H, Esbenshade AJ, Alexander S, Wiley JM, Sung L (2019) Effect of caspofungin vs fluconazole prophylaxis on invasive fungal disease among children and Young adults with acute myeloid leukemia: a randomized clinical trial. Jama 322(17):1673\u20131681. https:\/\/doi.org\/10.1001\/jama.2019.15702","journal-title":"Jama"},{"issue":"1","key":"4107_CR68","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1128\/aac.50.1.143-147.2006","volume":"50","author":"GN Mattiuzzi","year":"2006","unstructured":"Mattiuzzi GN, Alvarado G, Giles FJ, Ostrosky-Zeichner L, Cortes J, O'Brien S, Verstovsek S, Faderl S, Zhou X, Raad II, Bekele BN, Leitz GJ, Lopez-Roman I, Estey EH (2006) Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 50(1):143\u2013147. https:\/\/doi.org\/10.1128\/aac.50.1.143-147.2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"3\u20134","key":"4107_CR69","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1159\/000331860","volume":"88","author":"F Traunmuller","year":"2011","unstructured":"Traunmuller F, Popovic M, Konz KH, Smolle-Juttner FM, Joukhadar C (2011) Efficacy and safety of current drug therapies for invasive aspergillosis. Pharmacology 88(3\u20134):213\u2013224. https:\/\/doi.org\/10.1159\/000331860","journal-title":"Pharmacology"},{"issue":"12","key":"4107_CR70","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1111\/jphp.12780","volume":"69","author":"A Patil","year":"2017","unstructured":"Patil A, Majumdar S (2017) Echinocandins in antifungal pharmacotherapy. J Pharm Pharmacol 69(12):1635\u20131660. https:\/\/doi.org\/10.1111\/jphp.12780","journal-title":"J Pharm Pharmacol"},{"issue":"4","key":"4107_CR71","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1517\/13543784.14.4.489","volume":"14","author":"AH Groll","year":"2005","unstructured":"Groll AH, Stergiopoulou T, Roilides E, Walsh TJ (2005) Micafungin: pharmacology, experimental therapeutics and clinical applications. Expert Opin Investig Drugs 14(4):489\u2013509. https:\/\/doi.org\/10.1517\/13543784.14.4.489","journal-title":"Expert Opin Investig Drugs"},{"issue":"10","key":"4107_CR72","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1099\/jmm.0.001059","volume":"68","author":"PDD Rosa","year":"2019","unstructured":"Rosa PDD, Ramirez-Castrillon M, Borges R, Aquino V, Meneghello Fuentefria A, Zubaran Goldani L (2019) Epidemiological aspects and characterization of the resistance profile of Fusarium spp. in patients with invasive fusariosis. J Med Microbiol 68(10):1489\u20131496. https:\/\/doi.org\/10.1099\/jmm.0.001059","journal-title":"J Med Microbiol"},{"issue":"2","key":"4107_CR73","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.blre.2016.09.002","volume":"31","author":"L Pagano","year":"2017","unstructured":"Pagano L, Busca A, Candoni A, Cattaneo C, Cesaro S, Fanci R, Nadali G, Potenza L, Russo D, Tumbarello M, Nosari A, Aversa F (2017) Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. Blood Rev 31(2):17\u201329. https:\/\/doi.org\/10.1016\/j.blre.2016.09.002","journal-title":"Blood Rev"},{"issue":"12","key":"4107_CR74","doi-asserted-by":"publisher","first-page":"e405","DOI":"10.1016\/s1473-3099(19)30312-3","volume":"19","author":"OA Cornely","year":"2019","unstructured":"Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, Hoenigl M, Jensen HE, Lagrou K, Lewis RE, Mellinghoff SC, Mer M, Pana ZD, Seidel D, Sheppard DC, Wahba R, Akova M, Alanio A, Al-Hatmi AMS, Arikan-Akdagli S, Badali H, Ben-Ami R, Bonifaz A, Bretagne S, Castagnola E, Chayakulkeeree M, Colombo AL, Corzo-Leon DE, Drgona L, Groll AH, Guinea J, Heussel CP, Ibrahim AS, Kanj SS, Klimko N, Lackner M, Lamoth F, Lanternier F, Lass-Floerl C, Lee DG, Lehrnbecher T, Lmimouni BE, Mares M, Maschmeyer G, Meis JF, Meletiadis J, Morrissey CO, Nucci M, Oladele R, Pagano L, Pasqualotto A, Patel A, Racil Z, Richardson M, Roilides E, Ruhnke M, Seyedmousavi S, Sidharthan N, Singh N, Sinko J, Skiada A, Slavin M, Soman R, Spellberg B, Steinbach W, Tan BH, Ullmann AJ, Vehreschild JJ, Vehreschild M, Walsh TJ, White PL, Wiederhold NP, Zaoutis T, Chakrabarti A (2019) Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis 19(12):e405\u2013e421. https:\/\/doi.org\/10.1016\/s1473-3099(19)30312-3","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"4107_CR75","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1128\/aac.04569-14","volume":"59","author":"OA Cornely","year":"2015","unstructured":"Cornely OA, Bohme A, Schmitt-Hoffmann A, Ullmann AJ (2015) Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study. Antimicrob Agents Chemother 59(4):2078\u20132085. https:\/\/doi.org\/10.1128\/aac.04569-14","journal-title":"Antimicrob Agents Chemother"},{"key":"4107_CR76","doi-asserted-by":"publisher","unstructured":"Bose P, McCue D, Wurster S, Wiederhold NP, Konopleva M, Kadia TM, Borthakur G, Ravandi F, Masarova L, Takahashi K, Zeev E, Yilmaz M, Daver N, Pemmaraju N, Naqvi K, Rausch CR, Marx KR, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP (2020) Isavuconazole as primary anti-fungal prophylaxis in patients with acute myeloid leukemia or myelodysplastic syndrome: an open-label, prospective. Phase II Study Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa358","DOI":"10.1093\/cid\/ciaa358"},{"issue":"7","key":"4107_CR77","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/s1473-3099(16)00071-2","volume":"16","author":"FM Marty","year":"2016","unstructured":"Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR 3rd, Alangaden GJ, Brown JM, Fredricks DN, Heinz WJ, Herbrecht R, Klimko N, Klyasova G, Maertens JA, Melinkeri SR, Oren I, Pappas PG, Racil Z, Rahav G, Santos R, Schwartz S, Vehreschild JJ, Young JH, Chetchotisakd P, Jaruratanasirikul S, Kanj SS, Engelhardt M, Kaufhold A, Ito M, Lee M, Sasse C, Maher RM, Zeiher B, Vehreschild M (2016) Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis 16(7):828\u2013837. https:\/\/doi.org\/10.1016\/s1473-3099(16)00071-2","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"4107_CR78","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/myc.12731","volume":"61","author":"SC Mellinghoff","year":"2018","unstructured":"Mellinghoff SC, Bassetti M, Dorfel D, Hagel S, Lehners N, Plis A, Schalk E, Vena A, Cornely OA (2018) Isavuconazole shortens the QTc interval. Mycoses 61(4):256\u2013260. https:\/\/doi.org\/10.1111\/myc.12731","journal-title":"Mycoses"},{"issue":"1","key":"4107_CR79","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/cpdd.285","volume":"6","author":"R Townsend","year":"2017","unstructured":"Townsend R, Dietz A, Hale C, Akhtar S, Kowalski D, Lademacher C, Lasseter K, Pearlman H, Rammelsberg D, Schmitt-Hoffmann A, Yamazaki T, Desai A (2017) Pharmacokinetic evaluation of CYP3A4-mediated drug-drug interactions of Isavuconazole with rifampin, ketoconazole, midazolam, and ethinyl estradiol\/norethindrone in healthy adults. Clin Pharmacol Drug Dev 6(1):44\u201353. https:\/\/doi.org\/10.1002\/cpdd.285","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"7","key":"4107_CR80","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1093\/cid\/ciy260","volume":"67","author":"M Fung","year":"2018","unstructured":"Fung M, Schwartz BS, Doernberg SB, Langelier C, Lo M, Graff L, Tan M, Logan AC, Chin-Hong P, Babik JM (2018) Breakthrough invasive fungal infections on Isavuconazole prophylaxis and treatment: what is happening in the real-world setting? Clin Infect Dis 67(7):1142\u20131143. https:\/\/doi.org\/10.1093\/cid\/ciy260","journal-title":"Clin Infect Dis"},{"issue":"10","key":"4107_CR81","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1093\/cid\/ciy406","volume":"67","author":"CR Rausch","year":"2018","unstructured":"Rausch CR, DiPippo AJ, Bose P, Kontoyiannis DP (2018) Breakthrough fungal infections in patients with leukemia receiving Isavuconazole. Clin Infect Dis 67(10):1610\u20131613. https:\/\/doi.org\/10.1093\/cid\/ciy406","journal-title":"Clin Infect Dis"},{"issue":"5","key":"4107_CR82","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1093\/cid\/ciz282","volume":"70","author":"L Fontana","year":"2020","unstructured":"Fontana L, Perlin DS, Zhao Y, Noble BN, Lewis JS, Strasfeld L, Hakki M (2020) Isavuconazole prophylaxis in patients with hematologic malignancies and hematopoietic cell transplant recipients. Clin Infect Dis 70(5):723\u2013730. https:\/\/doi.org\/10.1093\/cid\/ciz282","journal-title":"Clin Infect Dis"},{"issue":"1","key":"4107_CR83","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00520-009-0783-3","volume":"19","author":"GN Mattiuzzi","year":"2011","unstructured":"Mattiuzzi GN, Cortes J, Alvarado G, Verstovsek S, Koller C, Pierce S, Blamble D, Faderl S, Xiao L, Hernandez M, Kantarjian H (2011) Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Support Care Cancer 19(1):19\u201326. https:\/\/doi.org\/10.1007\/s00520-009-0783-3","journal-title":"Support Care Cancer"},{"key":"4107_CR84","unstructured":"M\u00fcller C, FIetz C, Streichert T, Cornely OA, Stemler J, Wiesen M (2019) LC-MS\/MS-method for the determination of midostaurin\u2014a multitargeted tyrosine kinase inhibitor for the treatment of for acute myeloid leukemia. Paper presented at the 16. Jahrestagung der Deutschen Gesellschaft f\u00fcr Klinische Chemie und Laboratoriumsmedizin e.V., Magdeburg,"},{"issue":"1","key":"4107_CR85","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.vascn.2006.11.005","volume":"56","author":"T Illmer","year":"2007","unstructured":"Illmer T, Thiede HM, Thiede C, Bornhauser M, Schaich M, Schleyer E, Ehninger G (2007) A highly sensitive method for the detection of PKC412 (CGP41251) and its metabolites by high-performance liquid chromatography. J Pharmacol Toxicol Methods 56(1):23\u201327. https:\/\/doi.org\/10.1016\/j.vascn.2006.11.005","journal-title":"J Pharmacol Toxicol Methods"},{"key":"4107_CR86","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jchromb.2013.11.003","volume":"944","author":"P Bourget","year":"2014","unstructured":"Bourget P, Amin A, Chandesris MO, Vidal F, Merlette C, Hirsch I, Cabaret L, Carvalhosa A, Mogenet A, Frenzel L, Damaj G, Lortholary O, Hermine O (2014) Liquid chromatography-tandem mass spectrometry assay for therapeutic drug monitoring of the tyrosine kinase inhibitor, midostaurin, in plasma from patients with advanced systemic mastocytosis. J Chromatogr B Anal Technol Biomed Life Sci 944:175\u2013181. https:\/\/doi.org\/10.1016\/j.jchromb.2013.11.003","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"issue":"10","key":"4107_CR87","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1182\/blood-2006-04-015743","volume":"108","author":"M Levis","year":"2006","unstructured":"Levis M, Brown P, Smith BD, Stine A, Pham R, Stone R, Deangelo D, Galinsky I, Giles F, Estey E, Kantarjian H, Cohen P, Wang Y, Roesel J, Karp JE, Small D (2006) Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood 108(10):3477\u20133483. https:\/\/doi.org\/10.1182\/blood-2006-04-015743","journal-title":"Blood"},{"key":"4107_CR88","unstructured":"Lewis RE AML - In the era of FLT3 inhibitors. In: 9th Trends in Medical Mycology (TIMM-9), Nice, France, 2019. Nice,"},{"issue":"3","key":"4107_CR89","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.idc.2006.06.007","volume":"20","author":"D Andes","year":"2006","unstructured":"Andes D (2006) Pharmacokinetics and pharmacodynamics of antifungals. Infect Dis Clin N Am 20(3):679\u2013697. https:\/\/doi.org\/10.1016\/j.idc.2006.06.007","journal-title":"Infect Dis Clin N Am"},{"issue":"3","key":"4107_CR90","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1093\/cid\/civ885","volume":"62","author":"PE Verweij","year":"2016","unstructured":"Verweij PE, Chowdhary A, Melchers WJ, Meis JF (2016) Azole resistance in Aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles? Clin Infect Dis 62(3):362\u2013368. https:\/\/doi.org\/10.1093\/cid\/civ885","journal-title":"Clin Infect Dis"},{"issue":"2","key":"4107_CR91","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1093\/mmy\/myz039","volume":"58","author":"S Delliere","year":"2020","unstructured":"Delliere S, Rivero-Menendez O, Gautier C, Garcia-Hermoso D, Alastruey-Izquierdo A, Alanio A (2020) Emerging mould infections: get prepared to meet unexpected fungi in your patient. Med Mycol 58(2):156\u2013162. https:\/\/doi.org\/10.1093\/mmy\/myz039","journal-title":"Med Mycol"},{"issue":"9","key":"4107_CR92","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/myc.12960","volume":"62","author":"OA Cornely","year":"2019","unstructured":"Cornely OA, Hoenigl M, Lass-Florl C, Chen SC, Kontoyiannis DP, Morrissey CO, Thompson GR 3rd (2019) Defining breakthrough invasive fungal infection\u2014position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology. Mycoses 62(9):716\u2013729. https:\/\/doi.org\/10.1111\/myc.12960","journal-title":"Mycoses"},{"issue":"7","key":"4107_CR93","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.clml.2015.02.017","volume":"15","author":"BW Cooper","year":"2015","unstructured":"Cooper BW, Kindwall-Keller TL, Craig MD, Creger RJ, Hamadani M, Tse WW, Lazarus HM (2015) A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients. Clin Lymphoma Myeloma Leuk 15(7):428\u2013432.e422. https:\/\/doi.org\/10.1016\/j.clml.2015.02.017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"supplement 1","key":"4107_CR94","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1182\/blood-2018-99-113582","volume":"132","author":"RTT Maziarz","year":"2018","unstructured":"Maziarz RTT, Patnaik MM, Scott BL, Mohan SR, Deol A, Rowley SD, Kim D, Haines K, Bonifacio GJ, Rine P, Purkayastha D, Fernandez HF (2018) Radius: a phase 2 randomized trial investigating standard of care \u00b1 midostaurin after allogeneic stem cell transplant in FLT3-ITD-mutated AML. Blood 132(supplement 1):662\u2013662. https:\/\/doi.org\/10.1182\/blood-2018-99-113582","journal-title":"Blood"},{"issue":"18","key":"4107_CR95","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Erba HP, Di Stasi A, Stuart R, Olin R, Kasner M, Ciceri F, Chou WC, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon SS, Lee JH, Pardee T, Fathi AT, Liu C, Hasabou N, Liu X, Bahceci E, Levis MJ (2019) Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med 381(18):1728\u20131740. https:\/\/doi.org\/10.1056\/NEJMoa1902688","journal-title":"N Engl J Med"},{"issue":"3","key":"4107_CR96","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/2040620714532123","volume":"5","author":"SA Wander","year":"2014","unstructured":"Wander SA, Levis MJ, Fathi AT (2014) The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond. Ther Adv Hematol 5(3):65\u201377. https:\/\/doi.org\/10.1177\/2040620714532123","journal-title":"Ther Adv Hematol"},{"issue":"9","key":"4107_CR97","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1182\/blood-2016-07-730648","volume":"129","author":"S Knapper","year":"2017","unstructured":"Knapper S, Russell N, Gilkes A, Hills RK, Gale RE, Cavenagh JD, Jones G, Kjeldsen L, Grunwald MR, Thomas I, Konig H, Levis MJ, Burnett AK (2017) A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. Blood 129(9):1143\u20131154. https:\/\/doi.org\/10.1182\/blood-2016-07-730648","journal-title":"Blood"},{"key":"4107_CR98","doi-asserted-by":"publisher","unstructured":"Lin S, Shaik N, Martinelli G, Wagner AJ, Cortes J, Ruiz-Garcia A (2019) Population pharmacokinetics of Glasdegib in patients with advanced hematologic malignancies and solid tumors. J Clin Pharmacol. https:\/\/doi.org\/10.1002\/jcph.1556","DOI":"10.1002\/jcph.1556"},{"issue":"14","key":"4107_CR99","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/s40265-018-0978-3","volume":"78","author":"S Dhillon","year":"2018","unstructured":"Dhillon S (2018) Ivosidenib: first global approval. Drugs 78(14):1509\u20131516. https:\/\/doi.org\/10.1007\/s40265-018-0978-3","journal-title":"Drugs"},{"issue":"6","key":"4107_CR100","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","volume":"130","author":"EM Stein","year":"2017","unstructured":"Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, Stone RM, DeAngelo DJ, Levine RL, Flinn IW, Kantarjian HM, Collins R, Patel MR, Frankel AE, Stein A, Sekeres MA, Swords RT, Medeiros BC, Willekens C, Vyas P, Tosolini A, Xu Q, Knight RD, Yen KE, Agresta S, de Botton S, Tallman MS (2017) Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 130(6):722\u2013731. https:\/\/doi.org\/10.1182\/blood-2017-04-779405","journal-title":"Blood"},{"issue":"25","key":"4107_CR101","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","volume":"378","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, Pollyea DA, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM (2018) Durable remissions with Ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med 378(25):2386\u20132398. https:\/\/doi.org\/10.1056\/NEJMoa1716984","journal-title":"N Engl J Med"},{"issue":"4","key":"4107_CR102","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2217\/ijh-2016-0011","volume":"5","author":"G Castelli","year":"2016","unstructured":"Castelli G, Pelosi E, Testa U (2016) Targeted therapies in the treatment of adult acute myeloid leukemias: current status and future perspectives. Int J Hematol Oncol 5(4):143\u2013164. https:\/\/doi.org\/10.2217\/ijh-2016-0011","journal-title":"Int J Hematol Oncol"},{"key":"4107_CR103","doi-asserted-by":"publisher","first-page":"l5221","DOI":"10.1136\/bmj.l5221","volume":"366","author":"H Naci","year":"2019","unstructured":"Naci H, Davis C, Savovi\u0107 J, Higgins JPT, Sterne JAC, Gyawali B, Romo-Sandoval X, Handley N, Booth CM (2019) Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis. BMJ 366:l5221. https:\/\/doi.org\/10.1136\/bmj.l5221","journal-title":"BMJ"},{"key":"4107_CR104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jcpt.13077","volume":"00","author":"R Mancini","year":"2019","unstructured":"Mancini R, LaMontagne L, Williams T, Kreisle W, Petersen F (2019) Midostaurin and cyclosporine drug interaction: a case report. J Clin Pharm Ther 00:1\u20134. https:\/\/doi.org\/10.1111\/jcpt.13077","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"4107_CR105","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2125.2010.03773.x","volume":"71","author":"U Diczfalusy","year":"2011","unstructured":"Diczfalusy U, Nyl\u00e9n H, Elander P, Bertilsson L (2011) 4\u03b2-Hydroxycholesterol, an endogenous marker of CYP3A4\/5 activity in humans. Br J Clin Pharmacol 71(2):183\u2013189. https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03773.x","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"4107_CR106","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1586\/14787210.2014.856755","volume":"11","author":"PW Bergman","year":"2013","unstructured":"Bergman PW, Bjorkhem-Bergman L (2013) Is there a role for statins in fungal infections? Expert Rev Anti-Infect Ther 11(12):1391\u20131400. https:\/\/doi.org\/10.1586\/14787210.2014.856755","journal-title":"Expert Rev Anti-Infect Ther"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04107-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04107-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04107-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T23:43:10Z","timestamp":1623109390000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04107-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,8]]},"references-count":106,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["4107"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04107-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,8]]},"assertion":[{"value":"7 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"JS reports research grants from Basilea Pharmaceutica International Ltd. and travel grants from Meta-Alexander Foundation and from the German Society for Infectious Diseases (DGI) outside of the submitted work.PK has received non-financial scientific grants from Miltenyi Biotec GmbH, Bergisch Gladbach, Germany, and the Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany, and received lecture honoraria from Akademie f\u00fcr Infektionsmedizin e.V., Astellas Pharma, Gilead Sciences, GPR Academy Ruesselsheim, MSD Sharp & Dohme GmbH, and University Hospital, LMU Munich outside the submitted work.ChM reports travel grants from Munipharma, Amgen, Servier Deutschland GmbH.CaM reports no conflict of interest.OAC has received research grants from Actelion, Amplyx, Astellas, Basilea, Cidara, Da Volterra, F2G, Gilead, Janssen Pharmaceuticals, Medicines Company, MedPace, Melinta Therapeutics, Merck\/MSD, Pfizer, and Scynexis; is a consultant to Actelion, Allecra Therapeutics, Amplyx, Astellas, Basilea, Biosys UK Limited, Cidara, Da Volterra, Entasis, F2G, Gilead, Matinas, MedPace, Menarini Ricerche, Roche Diagnostics, Merck\/MSD, Nabriva Therapeutics, Octapharma, Paratek Pharmaceuticals, Pfizer, PSI, Rempex, Scynexis, Seres Therapeutics, Tetraphase, and Vical; and received lecture honoraria from Astellas, Basilea, Gilead, Grupo Biotoscana, Merck\/MSD, and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}